Dr. Jonathan Thompson, MD
Claim this profileMedical College of Wisconsin
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
23 drugs studied
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Non-Small Cell Lung Cancer
Stage III
Stage IV
PD-L1 positive
Affiliated Hospitals
Clinical Trials Jonathan Thompson, MD is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
CAR-GPC3 T Cell Therapy
for Cancer
This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.
Recruiting1 award Phase 1 & 2
More about Jonathan Thompson, MD
Clinical Trial Related4 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Jonathan Thompson, MD has experience with
- Pembrolizumab
- Radiation Therapy
- Osimertinib
- Carboplatin
- Atezolizumab
- Targeted TKI Therapy
Breakdown of trials Jonathan Thompson, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Neuroendocrine Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jonathan Thompson, MD specialize in?
Jonathan Thompson, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jonathan Thompson, MD currently recruiting for clinical trials?
Yes, Jonathan Thompson, MD is currently recruiting for 9 clinical trials in Milwaukee Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Jonathan Thompson, MD has studied deeply?
Yes, Jonathan Thompson, MD has studied treatments such as Pembrolizumab, Radiation Therapy, Osimertinib.
What is the best way to schedule an appointment with Jonathan Thompson, MD?
Apply for one of the trials that Jonathan Thompson, MD is conducting.
What is the office address of Jonathan Thompson, MD?
The office of Jonathan Thompson, MD is located at: Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States. This is the address for their practice at the Medical College of Wisconsin.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.